New paper from Italy, Istituto Superiore di Sanità, the Italian equivalent to NIH, have just a published a risk-benefit analysis of the mRNA vaccines.

Conclusion: The scientific community needs to be aware and discuss whether the use of the current genetic COVID-19 vaccines, which was justified at the time of earlier deadly coronavirus variants, should still be encouraged at the time of Omicron variants.

Pivot is coming.